Familial Cancer Registry Shared Resource - Claudine Isaacs, MD The Familial Cancer Registry (FCR) Shared Resource is a unique shared resource that provides investigators access to one of the nation?s largest collections of individuals from high-risk breast cancer families. The FCR is a comprehensive resource that includes detailed demographic data, family history information, medical history, cancer risk factors, tissue from surgeries (benign and malignant), immortalized lymphocytes, red blood cells, buffy coat, plasma, blood clot and serum, all of which can be linked confidentially to the results of genetic testing. The FCR has existed since 1998. In 2001 the FCR received developmental funds from the Cancer Center Support Grant of the Lombardi Comprehensive Cancer Center (Lombardi) to become a shared resource. Currently, 2,143 subjects are enrolled in the FCR, representing an increase of 1,119 individuals since the last grant submission. The FCR aims to provide interested investigators with high-quality data and biospecimens from a genetically characterized population that is at high risk of developing certain types of cancer. The FCR resources have supported important research in three Lombardi programs. Research topics have ranged from behavioral research (e.g., how genetic testing affects medical decision-making) to basic science (e.g., examining DNA repair gene polymorphisms in hereditary breast cancer). Fifty publications were supported by the FCR from 2003 through 2008. New developments in the FCR since the last application include the creation of tissue microarrays of breast tumors from women with a hereditary predisposition to this disease, the expansion of the FCR to recruit from another MedStar Hospital (Washington Hospital Center), and the recruitment of individuals with hereditary predisposition to colorectal cancer. Claudine Isaacs, MD, directs the FCR, is the Medical Director of the Cancer Assessment and Risk Evaluation (CARE) program, and is the codirector of the Fisher Center for Familial Cancer Research. Dr. Isaacs is an expert in the genetic factors that predispose to breast and other cancers. Her clinical interest also includes the treatment of patients with breast cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
United States
Zip Code
Bae, Woo Kyun; Yoo, Kyung Hyun; Lee, Ji Shin et al. (2015) The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog 54:1172-80
Adams, Inez; Christopher, Juleen; Williams, Karen Patricia et al. (2015) What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2. J Cancer Educ 30:344-52
Butrick, Morgan; Kelly, Scott; Peshkin, Beth N et al. (2015) Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genet Med 17:467-75
London, Laricca; Hurtado-de-Mendoza, Alejandra; Song, Minna et al. (2015) Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials 40:74-80
Mays, Darren; Niaura, Raymond S; Evans, W Douglas et al. (2015) Cigarette packaging and health warnings: the impact of plain packaging and message framing on young smokers. Tob Control 24:e87-92
Zhi, Xiuling; Lin, Ling; Yang, Shaoxian et al. (2015) ?II-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 61:598-612
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Heckler, Mary Mazzotta; Riggins, Rebecca B (2015) ERR? splice variants differentially regulate cell cycle progression. Cell Cycle 14:31-45
Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93
Tong, Angie; Kelly, Scott; Nusbaum, Rachel et al. (2015) Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology 24:33-9

Showing the most recent 10 out of 544 publications